Cargando…

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY

Detalles Bibliográficos
Autores principales:	Machowicz, Rafal, Lis, Karol, Rytel, Jagoda, Jachalska, Anna, Szwedyk, Pawel, Sosnia, Oktawia, Wiater, Elzbieta, Obara, Agata, Krochmalczyk, Dorota, Kopinska, Anna, Gajewska, Malgorzata, Masternak, Anna, Kopacz, Agnieszka, Olszewska-Szopa, Magdalena, Golos, Aleksandra, Subocz, Edyta, Drozd-Sokolowska, Joanna, Basak, Grzegorz, Mądry, Krzysztof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429968/ http://dx.doi.org/10.1097/01.HS9.0000974812.26724.39

Ejemplares similares

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

Software needs for MDs
por: Ruggiero, F
Publicado: (1993)

LHC MDS For 2018
por: Tomás, R, et al.
Publicado: (2019)

Bogus "M.Ds."
por: Karnik, C. H.
Publicado: (1929)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

PS Beams for SPS MDs
por: Manglunki, Django
Publicado: (1998)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

William Jarvie, M.D.S.
Publicado: (1922)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Results of MD’s in Autumn 1988 on e+
por: Canard, B, et al.
Publicado: (1989)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Targeting the Microenvironment in MDS: The Final Frontier
por: Teodorescu, Patric, et al.
Publicado: (2020)

High-risk MDS after HMAs
por: Adès, Lionel
Publicado: (2019)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

The Coming of Age of Preclinical Models of MDS
por: Liu, Wei, et al.
Publicado: (2022)

Stewart Bailey Palmer, M.D.S.
Publicado: (1903)

Stewart B. Palmer, M.D.S.
Publicado: (1903)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
por: Calvete, Oriol, et al.
Publicado: (2023)

RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS
por: Kaisrlikova, Monika, et al.
Publicado: (2022)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

Downregulation of MMP1 in MDS-derived mesenchymal stromal cells reduces the capacity to restrict MDS cell proliferation
por: Zhao, Sida, et al.
Publicado: (2017)

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
por: de Swart, Louise, et al.
Publicado: (2017)

The Ghost Train Instability (MDs 2066 and 2936)
por: Carver, Lee Robert, et al.
Publicado: (2018)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Observations of beam-beam effects in MDs in 2011
por: Herr, W, et al.
Publicado: (2012)

Hematopoietic Cell Transplantation for Older Patients with MDS
por: Shadman, Mazyar, et al.
Publicado: (2014)

Controversies on the Consequences of Iron Overload and Chelation in MDS
por: Vinchi, Francesca, et al.
Publicado: (2020)

Editorial: Advancing Science for Clinical Care in MDS
por: Figueroa, Maria E., et al.
Publicado: (2022)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

VEXAS Syndrome: A Novelty in MDS Landscape
por: Templé, Marie, et al.
Publicado: (2022)

Interaction Mediated by the Putative Tip Regions of MdsA and MdsC in the Formation of a Salmonella-Specific Tripartite Efflux Pump
por: Song, Saemee, et al.
Publicado: (2014)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways
por: Guerenne, Laura, et al.
Publicado: (2016)

P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

Down Selection Criteria and MDs Prior to LS3
por: Arduini, G
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cr74vghpoish6h0u4aatpqaqre